Sector: Biotechnology

There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.    Read More

Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.   Read More

Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.   Read More

Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.    Read More

Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.   Read More

Find out why he’s bullish on this biotech name.   Read More

As the JPMorgan Health Care conference kicks off this week, one question remains for investors in the biotech space. What’s the next takeover target as large drug makers look to build out their pipeline?   Read More

The No. 5 performer in the top S&P stocks of 2011 could see more growth ahead, one “Fast Money” pro said.    Read More

Targacept has been exiled to the woodshed, but yesterday the buyers came back in force.    Read More

Cramer goes one-on-one with Questcor CEO Don Bailey to find out more about the company.    Read More